Blinatumomab: 14 agencies, 2015–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
On the same population the two systems disagree outright: SMC (Scotland) recorded recommended for “the treatment of adults with Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL).”, while PBAC (Australia) recorded not recommended for “Philadelphia chromosome-negative relapsed or refractory B-precursor acute lymphoblastic leukaemia”.
Assessment has run over 11.1 years, from 2015 at PBAC (Australia) to 12 Aug 2026 at AIFA (Italy).
NYE METODER (Norway) changed its position: not recommended on 12 Jun 2016, recommended by 15 Mar 2026, after a resubmission.
No assessment is on file from TLV (Sweden), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for blinatumomab, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 26 of 64 records date from 2023 or later.
The programme is broad: 17 distinct indication wordings are recorded for blinatumomab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
12 of these 64 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess blinatumomab, in 2015; HIRA (South Korea) did not open a file until 2 Apr 2026 — an unusually long tail of 10.8 years between the earliest and latest system to look at it.
The record arrives in waves: 9 separate years each carry two or more decisions, spread across 12 years in total.
11 of the 14 agencies here assessed blinatumomab more than once, PBAC (Australia) most often at 12 entries — repeat review is the norm for this molecule rather than the exception.
blinatumomab has been through 14 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for blinatumomab reads 32 recommended, 11 restricted, 7 not recommended and 4 no benefit, with 10 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2026 | Acute lymphoblastic leukaemia (ALL) | Precursor B-cell ALL (Pre-B-cell ALL) | Recommended | source |
| HIRA (South Korea) | 2 Apr 2026 | 성인 및 소아에서 필라델피아 염색체 음성인 전구 B 세포 급성 림프모구성 백혈병 (ALL) 의 관해 공고 요법 치료 | extension of coverage appropriate (risk-share extension) | source |
| DMC (Denmark) | 21 Jan 2026 | Blinatumomab er indiceret som monoterapi som en del af konsolideringsbehandlingen af voksne patienter med nydiagnosticer… | Anbefalet | source |
| SMC (Scotland) | 8 Sep 2025 | Treatment of adult patients with Philadelphia chromosome (Ph)-negative, CD19-positive, B-cell precursor acute lymphoblastic leukaemia (ALL) in the consolidation phase. | accepted (restricted) | source |
| NYE METODER (Norway) | 19 Jan 2025 | Legemiddel som bro til transplantasjon hos pasienter med avansert B-prekursor akutt lymfoblastisk leukemi (ALL) | decision recorded | source |
59 further decisions for blinatumomab, across 12 agencies, are not shown here. They include the most recent record on file, 12 Aug 2026 from AIFA (Italy); its outcome is in the subscriber dataset. They link to 39 further source documents.
Related molecules
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
- rituximab — same ATC class L01F — Antineoplastics
- bevacizumab — same ATC class L01F — Antineoplastics
- trastuzumab deruxtecan — same ATC class L01F — Antineoplastics
Coverage: 64 decisions for blinatumomab from 14 agencies, 2015 to 2026. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.